263 related articles for article (PubMed ID: 10940280)
41. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
42. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
43. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis.
Swidsinski A; Loening-Baucke V; Bengmark S; Lochs H; Dörffel Y
Inflamm Bowel Dis; 2007 Jan; 13(1):51-6. PubMed ID: 17206639
[TBL] [Abstract][Full Text] [Related]
44. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients.
Lobatón T; Bessissow T; De Hertogh G; Lemmens B; Maedler C; Van Assche G; Vermeire S; Bisschops R; Rutgeerts P; Bitton A; Afif W; Marcus V; Ferrante M
J Crohns Colitis; 2015 Oct; 9(10):846-52. PubMed ID: 26116558
[TBL] [Abstract][Full Text] [Related]
45. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
46. Histological healing after infliximab induction therapy in children with ulcerative colitis.
Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
[TBL] [Abstract][Full Text] [Related]
47. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
[TBL] [Abstract][Full Text] [Related]
48. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis.
Beattie RM; Nicholls SW; Domizio P; Williams CB; Walker-Smith JA
J Pediatr Gastroenterol Nutr; 1996 May; 22(4):373-9. PubMed ID: 8732900
[TBL] [Abstract][Full Text] [Related]
49. Extensive colonic mucosal defect induced by mesalamine.
Kato J; Yoshida T; Kitano M
Dig Endosc; 2018 May; 30(3):390-391. PubMed ID: 29469941
[No Abstract] [Full Text] [Related]
50. Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis.
Eliakim R; Karmeli F; Chorev M; Okon E; Rachmilewitz D
Scand J Gastroenterol; 1992 Nov; 27(11):968-72. PubMed ID: 1455196
[TBL] [Abstract][Full Text] [Related]
51. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
[TBL] [Abstract][Full Text] [Related]
52. A comprehensive review and update on ulcerative colitis
Gajendran M; Loganathan P; Jimenez G; Catinella AP; Ng N; Umapathy C; Ziade N; Hashash JG
Dis Mon; 2019 Dec; 65(12):100851. PubMed ID: 30837080
[TBL] [Abstract][Full Text] [Related]
53. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
54. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study.
Yokoyama H; Takagi S; Kuriyama S; Takahashi S; Takahashi H; Iwabuchi M; Takahashi S; Kinouchi Y; Hiwatashi N; Tsuji I; Shimosegawa T
Inflamm Bowel Dis; 2007 Sep; 13(9):1115-20. PubMed ID: 17455207
[TBL] [Abstract][Full Text] [Related]
55. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.
Ardizzone S; Maconi G; Russo A; Imbesi V; Colombo E; Bianchi Porro G
Gut; 2006 Jan; 55(1):47-53. PubMed ID: 15972298
[TBL] [Abstract][Full Text] [Related]
56. Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission.
Wakai M; Hayashi R; Tanaka S; Naito T; Kumada J; Nomura M; Takigawa H; Oka S; Ueno Y; Ito M; Chayama K
BMC Gastroenterol; 2020 Apr; 20(1):85. PubMed ID: 32245401
[TBL] [Abstract][Full Text] [Related]
57. Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis.
Takahashi F; Tominaga K; Kanamori A; Takenaka K; Hoshino A; Sugaya T; Nakano M; Hiraishi H
Scand J Gastroenterol; 2016 Jul; 51(7):827-34. PubMed ID: 26853910
[TBL] [Abstract][Full Text] [Related]
58. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?
Hindryckx P; Novak G
Best Pract Res Clin Gastroenterol; 2018; 32-33():9-15. PubMed ID: 30060944
[TBL] [Abstract][Full Text] [Related]
59. Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?
Wolff S; Terheggen G; Mueller R; Greinwald R; Franklin J; Kruis W
Inflamm Bowel Dis; 2013 Nov; 19(12):2611-5. PubMed ID: 24108110
[TBL] [Abstract][Full Text] [Related]
60. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis.
Kawashima K; Ishihara S; Yuki T; Fukuba N; Oshima N; Kazumori H; Sonoyama H; Yamashita N; Tada Y; Kusunoki R; Oka A; Mishima Y; Moriyama I; Kinoshita Y
BMC Gastroenterol; 2016 Apr; 16():47. PubMed ID: 27071448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
